Details
|
ZymoGenetics, Inc. is engaging in development, discovering, and commercialization of protein-based therapeutic products indicated for human diseases treatment. Company’s products include NovoRapid and Novolin distributed around the world for hemophilia treatment, Cleactor for heart attacks and myocardial infarction treatment, GlucaGen for treatment of serious hypoglycemia in diabetics treated with insulin and for use as an aid for gastrointestinal motility inhibition, Regranex for the wound healing treatment, and NovoSeven for the hemophilia treatment. ZymoGenetics, inc. product pipeline offers rhThrombin, IL-21, and TACI-lg. Taci-lg is soluble receptor indicated for autoimmune diseases treatment and in combination with IL-21 as a protein for cancer treatment. rhThrombin is a hemostatic topical agent indicated for controlling bleeding during surgeries and has completed Phase two clinical study. The company was discovered by Michael Smith, Benjamin D. Hall, and Earl W. Davie. ZymoGenetics is based in Seattle, Washington and trade under the name ZGEN. website www.zymogenetics.com (phone 206-442-6608).
|
